Anne-Isabelle Michou

Title: The Innovative Contributions of Anne-Isabelle Michou

Introduction

Anne-Isabelle Michou is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of viral vectors for vaccine and gene therapy applications. With a total of 2 patents, her work has the potential to impact both animal and human health.

Latest Patents

Her latest patents include the Recombinant CELO virus and CELO virus DNA, which feature a deletion at the right end of the viral genome. This modification allows for the insertion of large pieces of foreign DNA, making the virus useful as a vaccine for animals, especially birds, as well as for gene therapy and vaccine applications in humans. Additionally, the virus can be utilized for recombinant protein production. Another patent involves a recombinant, replication-defective CELO virus and CELO virus DNA, which includes a deletion or disruption of the Gam1 gene. This version also allows for the insertion of large pieces of foreign DNA, further enhancing its utility in vaccine and gene therapy applications.

Career Highlights

Anne-Isabelle Michou is currently employed at Boehringer Ingelheim International GmbH, where she continues to advance her research in viral vectors. Her innovative work has positioned her as a key figure in the biotechnology sector.

Collaborations

She collaborates with notable colleagues, including Matthew Cotten and Amelia Compagni, who contribute to her research endeavors.

Conclusion

Anne-Isabelle Michou's contributions to biotechnology through her patents and research at Boehringer Ingelheim International GmbH highlight her role as an influential inventor in the field. Her work promises to advance vaccine and gene therapy technologies, benefiting both animals and humans.